Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman Sells 60,984 Shares

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 60,984 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $1.50, for a total value of $91,476.00. Following the transaction, the chief executive officer now owns 4,309,758 shares of the company’s stock, valued at $6,464,637. This trade represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

William Mariner Greenman also recently made the following trade(s):

• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The stock was sold at an average price of $1.55, for a total value of $35,685.65.

Cerus Trading Down 2.6 %

CERS stock opened at $1.47 on Tuesday. The business has a fifty day moving average price of $1.74 and a 200 day moving average price of $1.79. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.54. The stock has a market capitalization of $273.11 million, a price-to-earnings ratio of -13.36 and a beta of 1.56. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The firm had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. Analysts expect that Cerus Co. will post -0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Institutional Investors Weigh In On Cerus

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in Cerus by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock valued at $7,685,000 after purchasing an additional 69,950 shares in the last quarter. State Street Corp increased its stake in shares of Cerus by 2.2% in the 3rd quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock valued at $6,506,000 after buying an additional 79,505 shares during the period. Barclays PLC increased its stake in shares of Cerus by 16.2% in the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock valued at $2,740,000 after buying an additional 219,755 shares during the period. Stifel Financial Corp increased its stake in shares of Cerus by 12.0% in the 3rd quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock valued at $461,000 after buying an additional 28,383 shares during the period. Finally, ARK Investment Management LLC increased its stake in shares of Cerus by 14.2% in the 4th quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company’s stock valued at $32,055,000 after buying an additional 2,589,721 shares during the period. 78.37% of the stock is owned by institutional investors and hedge funds.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.